Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases

Abstract

Neurodegenerative diseases are a group of debilitating pathologies in which neuronal tissue dies due to the buildup of neurotoxic plaques, resulting in detrimental effects on cognitive ability, motor control, and everyday function. Stem cell technology offers promise in addressing this problem on multiple fronts, but the conventional sourcing of pluripotent stem cells involves harvesting from aborted embryonic tissue, which comes with strong ethical and practical concerns. The keystone discovery of induced pluripotent stem cell (iPSC) technology provides an alternative and endless source, circumventing the unfavorable issues with embryonic stem cells, and yielding fundamental advantages. This review highlights iPSC technology, the pathophysiology of two major neurodegenerative diseases, Alzheimer's and Parkinson's, and then illustrates current state-of-the-art approaches towards the treatment of the diseases using iPSCs. The technologies discussed in the review emphasize in vitro therapeutic neural cell and organoid development for disease treatment, pathological modeling of neurodegenerative diseases, and 3D bioprinting as it applies to both.

Keywords: 3D bioprinting; Alzheimer’s disease; Parkinson’s disease; induced pluripotent stem cells; neural cells; neural organoids.

Figure 1

iPSCs for the treatment of neurodegenerative diseases. iPSCs are reprogrammed from the patient’s somatic cells. Their derived cells can be implanted directly or used to fabricate constructs for drug testing. Bioprinting can be applied to achieve the expected tissue structure of the engineered constructs.